Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.53Last Year’s EPS
-0.65Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 5.42%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the development of certepetide, including regulatory achievements and a reduction in operating expenses. However, low revenue generation and ongoing net losses pose challenges. The uncertainty surrounding the release of key trial data further complicates the outlook.Company Guidance
During the Lisata Therapeutics' Full Year 2024 Financial Results and Business Update Conference Call, the company reported key financial metrics and provided guidance on upcoming milestones. For the fiscal year ending December 31, 2024, Lisata generated $1 million in revenue, primarily from an upfront license fee, and incurred operating expenses totaling $23.4 million, a decrease of $2.3 million from 2023. Research and development expenses dropped by $1.4 million to $11.3 million, largely due to reduced costs for the Phase 2b ASCEND trial, while general and administrative expenses decreased by $0.9 million to $12.1 million. The net loss for 2024 was $20 million, slightly improved from the $20.8 million loss in 2023. Cash reserves stood at $31.2 million, projected to sustain operations into Q2 2026. Key upcoming milestones in 2025 include data releases from various clinical trials involving certepetide in cancer and other therapeutic areas, with a focus on advancing clinical and preclinical programs.Advancement of Certepetide Development Portfolio
Lisata has advanced its development portfolio centered around certepetide for treating advanced solid tumors. Encouraging preliminary results from the ASCEND and iLSTA trials were presented at the 2025 ASCO GI Symposium.
Operating Expense Reduction
Operating expenses for 2024 totaled $23.4 million, a decrease of $2.3 million or 8.9% from 2023.
Cash Reserves and Funding
As of December 31, 2024, Lisata had cash, cash equivalents, and marketable securities of approximately $31.2 million, expected to support operations into Q2 2026.
Regulatory Achievements
Certepetide received several orphan drug designations, a fast track designation, and a rare pediatric disease designation in multiple jurisdictions.
---
LSTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LSTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $2.40 | $2.38 | -0.83% |
| Nov 12, 2024 | $2.91 | $2.79 | -4.12% |
| Aug 12, 2024 | $2.93 | $2.94 | +0.34% |
| May 09, 2024 | $2.91 | $2.95 | +1.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lisata Therapeutics (LSTA) report earnings?
Lisata Therapeutics (LSTA) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Lisata Therapeutics (LSTA) earnings time?
Lisata Therapeutics (LSTA) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LSTA EPS forecast?
LSTA EPS forecast for the fiscal quarter 2025 (Q1) is -0.53.
---